HU6

维基百科,自由的百科全书
HU6
法律規範狀態
法律規範
  • Investigational
识别信息
  • 5-[(2,4-Dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole
CAS号2231311-68-3
PubChem CID
化学信息
化学式C11H9N5O7
摩尔质量323.22 g·mol−1
3D模型(JSmol英语JSmol
  • CN1C(=CN=C1[N+](=O)[O-])COC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-]

HU6是线粒体解偶联剂2,4-二硝基苯酚(DNP) 的前药,其旨在最大限度地减慢DNP的吸收速度并削减,以提供更广泛的治疗指数并提高安全性。该药物由 Rivus Pharmaceuticals 开发,经过测试可减轻代谢功能障碍相关脂肪性肝病并伴危险因素的人群的体重及其肝脏脂肪含量。在 2a 期试验中,在较高的剂量下,肝脏脂肪平均减少了 30% 以上,并且体重显著减轻。[1] [2]其2b 期试验已于 2023 年底启动。[3]

参考文献

  1. ^ Harrison, Stephen A.; Loomba, Rohit; Dubourg, Julie; Ratziu, Vlad; Noureddin, Mazen. Clinical Trial Landscape in NASH. Clinical Gastroenterology and Hepatology. 2023-07, 21 (8): 2001–2014. doi:10.1016/j.cgh.2023.03.041 (英语). 
  2. ^ Noureddin, Mazen; Khan, Shaharyar; Portell, Francisco; Jorkasky, Diane; Dennis, Jameel; Khan, Omer; Johansson, Lars; Johansson, Edvin; Sanyal, Arun J. Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial. The Lancet Gastroenterology & Hepatology. 2023-12, 8 (12): 1094–1105. doi:10.1016/S2468-1253(23)00198-X (英语). 
  3. ^ Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments. Yahoo Finance. 2023-11-15 [2024-02-23] (美国英语).